7/108 sources · 4 publishersUpdated Nov 9, 13:05 UTC
Ocular Therapeutix reports Q3 2026 loss and revenue miss
+3 new sources since this summary was written
Ocular Therapeutix posted third‑quarter 2026 GAAP loss of $0.42 per share on net loss of $94.8 million. Revenue fell 11.5% year‑over‑year to $12.87 million, missing consensus estimates by about $1.0 million. Selling and marketing expenses rose to $15.7 million and R&D to $74.8 million, while cash and cash equivalents stood at $530.6 million. The stock dropped 7.4% after the release.
Why it matters
The earnings miss and widening loss drove the share price down 7.4%. The sizable cash balance of $530.6 million should fund operations into 2028, limiting immediate financing risk.
Key facts
- 1GAAP loss per share was $‑0.42. seekingalpha.com
- 2Net loss for the quarter was $94.8 million. tradingview.com
- 3Revenue was $12.87 million, down 11.5% YoY. finance.yahoo.com
- 4Selling and marketing expenses increased to $15.7 million. seekingalpha.com
- 5Research and development expenses were $74.8 million. tradingview.com
- 6Cash and cash equivalents totaled $530.6 million at September 30, 2026. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.